Josias Pontes - Jun 14, 2021 Form 3 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Jun 14, 2021
Transactions value $
$0
Form type
3
Date filed
6/21/2021, 04:20 PM
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGTX Common Stock 600 Jun 14, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGTX Stock Option (Right to Buy) Jun 14, 2021 Common Stock 66.7K $8.87 Direct F1
holding SGTX Stock Option (Right to Buy) Jun 14, 2021 Common Stock 888 $9.39 Direct F2
holding SGTX Stock Option (Right to Buy) Jun 14, 2021 Common Stock 25K $39.81 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the underlying shares of common stock on December 5, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F2 The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option shall vest as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date.
F3 The option vests as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.